A	B	C
1	Main
2		Brand Name
3		Generic Name	ipilimumab
4		Mechanism	CTLA4 antibody
5		Indication	2L melanoma
6		Economics	MEDX
7		Clinical Trials
8			Phase III
9
10
11			Phase III comparing gp100, ipi+gp100 vs ipi alone
12			Ipi-alone and Ipi+gp100 both S.S. vs. gp100 (HR=0.66, 0.68). 10.0, 10.1 and 6.4 months for Ipi, ipi+gp100 and gp100.
13
14			Phase I/II mixed leukemias/lymphomas n=17 single-dose, dose-escalation
15			1 NHL patient had ongoing CR, 1 MCL with PR
16
17			Phase I/II relapsed/refractory follicular lymphoma n=12
18			1 patient with a PR